2024
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2024, 134: e180583. PMID: 38488004, PMCID: PMC10940080, DOI: 10.1172/jci180583.Peer-Reviewed Original Research
2023
Hiding in Plain Sight: Catastrophic Diethylene Glycol Poisoning in Children
Perazella M. Hiding in Plain Sight: Catastrophic Diethylene Glycol Poisoning in Children. Kidney360 2023, 4: 1534-1535. PMID: 37831818, PMCID: PMC10695641, DOI: 10.34067/kid.0000000000000269.Peer-Reviewed Original ResearchA Patient with an Unusual Cause of AKI and Scrotal Swelling
Gomez D, Perazella M. A Patient with an Unusual Cause of AKI and Scrotal Swelling. Kidney360 2023, 4: 1188-1189. PMID: 37651667, PMCID: PMC10484347, DOI: 10.34067/kid.0000000000000125.Peer-Reviewed Original ResearchIdentification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatientsContrast-Induced Acute Kidney Injury and Cardiovascular Imaging: Danger or Distraction?
Davenport M, Perazella M, Nallamothu B. Contrast-Induced Acute Kidney Injury and Cardiovascular Imaging: Danger or Distraction? Circulation 2023, 147: 847-849. PMID: 36913495, DOI: 10.1161/circulationaha.122.062783.Peer-Reviewed Original ResearchAcquired Disorders of Hypomagnesemia
Rosner M, Ha N, Palmer B, Perazella M. Acquired Disorders of Hypomagnesemia. Mayo Clinic Proceedings 2023, 98: 581-596. PMID: 36872194, DOI: 10.1016/j.mayocp.2022.12.002.Peer-Reviewed Original ResearchConceptsReduced glomerular filtration rateBody storesBody magnesium storesGlomerular filtration rateSerum magnesium levelsTotal body storesDevelopment of symptomsIntravenous replacementOrgan dysfunctionMagnesium disordersRenal lossMagnesium replacementFiltration rateSevere casesMagnesium storesHypomagnesemiaClinical experienceClinical practiceMagnesium levelsAcquired disordersAmphotericin BMagnesium handlingOptimal managementMedicationsLaboratory assessment
2022
Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original ResearchImmune checkpoints inhibitors and its link to acute kidney injury and renal prognosis
Kanbay M, Yildiz AB, Siriopol D, Vehbi S, Hasbal NB, Kesgin YE, Celayir M, Selcukbiricik F, Covic A, Perazella MA. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology And Nephrology 2022, 55: 1025-1032. PMID: 36282399, DOI: 10.1007/s11255-022-03395-y.Peer-Reviewed Original ResearchConceptsAcute kidney injuryImmune checkpoint inhibitorsSolid organ malignanciesCheckpoint inhibitorsKidney injuryOrgan malignanciesNephrotoxic agentsSingle-center retrospective cohort studyType of ICIBaseline serum creatinine levelAcute interstitial nephritisLocation of malignancyRetrospective cohort studySerum creatinine levelsKidney function recoveryRenal replacement therapyUrinary tract obstructionRisk of mortalityICPI treatmentRenal prognosisTract obstructionCohort studyCreatinine levelsFive patientsInterstitial nephritisVancomycin Should Be Considered a Nephrotoxic Antimicrobial Agent: COMMENTARY
Perazella MA. Vancomycin Should Be Considered a Nephrotoxic Antimicrobial Agent: COMMENTARY. Kidney360 2022, 3: 1491-1493. PMID: 36250736, PMCID: PMC9528384, DOI: 10.34067/kid.0008112021.Peer-Reviewed Original ResearchDiagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapyDrug-Induced Acute Kidney Injury
Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1220-1233. PMID: 35273009, PMCID: PMC9435983, DOI: 10.2215/cjn.11290821.Peer-Reviewed Original ResearchConceptsKidney injuryTubular injuryDrug-induced acute kidney injuryT cell-mediated immune responsesDrug-related kidney injuryCell-mediated immune responsesAcute interstitial nephritisDirect tubular injuryTreatment of AKIAcute kidney injuryAcute tubular injuryIntensive care unitInduction of inflammationAKI riskIntratubular obstructionTubulointerstitial injuryInterstitial nephritisCare unitInflammation leadInjury resultsCommon causeImmune responseHospital wardsProximal tubulesAKIDrug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?
Perazella MA, Juncos LA. Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List? Kidney360 2022, 3: 550-553. PMID: 35582186, PMCID: PMC9034826, DOI: 10.34067/kid.0007882021.Peer-Reviewed Original ResearchMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activationSevere AKI in a Patient on Multiple Antimicrobial Agents for Leg Infection
Rehan A, Moeckel GW, Perazella MA. Severe AKI in a Patient on Multiple Antimicrobial Agents for Leg Infection. Kidney360 2022, 3: 405-406. PMID: 35373119, PMCID: PMC8967631, DOI: 10.34067/kid.0006102021.Peer-Reviewed Original Research
2021
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogenImmunotherapy-Related Acute Kidney Injury
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Advances In Kidney Disease And Health 2021, 28: 429-437.e1. PMID: 35190109, DOI: 10.1053/j.ackd.2021.07.006.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyEffective immune checkpoint inhibitorsAcute kidney injuryImmune checkpoint inhibitorsHigh-dose interleukinNumerous clinical trialsT-cell therapyField of oncologyCheckpoint inhibitorsKidney injuryGeneration immunotherapiesClinical trialsClinical practiceImmunotherapyImmune systemAdverse effectsNephrotoxicityInterleukinPathophysiologyInjuryTherapyCancerOncologyTrialsThe Challenges of Acute Interstitial Nephritis: Time to Standardize
Moledina DG, Perazella MA. The Challenges of Acute Interstitial Nephritis: Time to Standardize. Kidney360 2021, 2: 1051-1055. PMID: 35373086, PMCID: PMC8791367, DOI: 10.34067/kid.0001742021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHumansNephritis, Interstitial
2020
Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY.
Baker ML, Perazella MA. Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY. Kidney360 2020, 1: 1192-1194. PMID: 35372870, PMCID: PMC8815502, DOI: 10.34067/kid.0004652020.Commentaries, Editorials and LettersUse of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 298: 202903. PMID: 33170103, DOI: 10.1148/radiol.2020202903.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaSimultaneous joint publicationKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskUrine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete data